EMEA-002575-PIP02-20
Key facts
Invented name |
Gavreto
|
Active substance |
pralsetinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0271/2021
|
PIP number |
EMEA-002575-PIP02-20
|
Pharmaceutical form(s) |
Capsule, hard
|
Condition(s) / indication(s) |
Treatment of thyroid cancer
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6168 79411 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|